All articles
ComplianceNovember 9, 2026·3 min read

Writing Recruitment Ads That Clear IRB on the First Pass

A practical guide to writing recruitment ads that clear IRB review on the first pass — the phrases that get flagged, safer alternatives, and a reusable template structure.

By Trialflow Team

Most recruitment ad rejections aren't about bad intentions. They're about language that drifted into promising something the protocol can't deliver, or formatting that made the IRB reviewer guess. Both are avoidable if you write the ad the way a reviewer reads it.

What the IRB is actually checking

Reviewers are applying a short mental checklist. Your ad should answer each item plainly:

  • Is it clear this is research, not treatment?
  • Is the condition and basic eligibility stated accurately?
  • Is the site identified, with a real contact method?
  • Is compensation described without being the headline?
  • Are there any claims of safety, effectiveness, or superiority?
  • Does the tone avoid coercion or undue influence?

If a reviewer can tick all six in under a minute, you'll usually clear with no changes.

The phrases that get ads sent back

Some wording fails almost every time. Build a house list and circulate it to anyone who writes copy.

Avoid:

  • "New treatment" or "breakthrough therapy" — implies proven benefit. Use "investigational study drug" or "study medication."
  • "Free treatment" — the study drug isn't treatment, and nothing framed as free is neutral. Use "study-related care at no cost to you."
  • "Safe and effective" — that's the question the trial exists to answer.
  • "Earn up to $1,200!" as the lead line — compensation can be mentioned, but it can't be the hook. Most IRBs want it de-emphasized in both placement and font size.
  • "Guaranteed," "proven," "cure," "no risk."
  • "Act now" or countdown urgency — reads as pressure.

Safer constructions:

  • "You may be eligible to participate in a clinical research study."
  • "Participants will be compensated for time and travel."
  • "Study-related visits, exams, and study medication are provided at no cost."
  • "Participation is voluntary. You may leave the study at any time."

Build from a reusable skeleton

Write one approved template per therapeutic area and swap the specifics. A workable structure:

  1. Condition-first headline — "Living with chronic migraine?"
  2. One sentence identifying it as a research study.
  3. Three to five eligibility bullets in plain language, pulled directly from inclusion criteria, not paraphrased loosely.
  4. What participation involves — number of visits, rough duration.
  5. Compensation, one line, no exclamation point.
  6. Site name, phone, and PI name if your IRB requires it.
  7. Required footer language your IRB mandates.

Templates cut review cycles dramatically because the reviewer recognizes the format and only has to check what changed.

Don't forget the channel-specific pieces

IRBs review the full recruitment artifact, not just the text. For digital ads, that means the image, the landing page, the pre-screener questions, and often the ad headline variants. Sites commonly get tripped up by submitting approved copy but running an unapproved thumbnail, or by A/B testing headlines that were never reviewed.

Submit every variant you plan to run. If you use social platforms, include targeting parameters — some IRBs want to confirm you aren't targeting in a way that implies you already know someone's diagnosis.

Keep a version log

Maintain a single sheet with ad ID, approval date, IRB approval number, channels it's approved for, and expiration. During monitoring visits and audits, the question is rarely "was this approved?" It's "can you show me which version ran and when." Screenshot every live ad on launch day and file it against the approval. That five-minute habit prevents the worst kind of finding.

Enrolling studies shouldn't be this hard

Trialflow gives research sites one platform for lead management, AI trial matching, and recruitment analytics.

Request a Demo